Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2014

  • May 2014
  • -
  • Global Markets Direct
  • -
  • 74 pages

Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2014’, provides an overview of the Inovio Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Inovio Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Inovio Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Inovio Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Inovio Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate Inovio Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Inovio Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Inovio Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Inovio Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Inovio Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Inovio Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Inovio Pharmaceuticals, Inc. Snapshot 7
Inovio Pharmaceuticals, Inc. Overview 7
Key Information 7
Key Facts 7
Inovio Pharmaceuticals, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Inovio Pharmaceuticals, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Pipeline Products - Out-Licensed Products 16
Out-Licensed Products/Combination Treatment Modalities 17
Inovio Pharmaceuticals, Inc. - Pipeline Products Glance 18
Inovio Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Inovio Pharmaceuticals, Inc. - Early Stage Pipeline Products 21
Preclinical Products/Combination Treatment Modalities 21
Inovio Pharmaceuticals, Inc. - Drug Profiles 23
VGX-3100 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
H1N1 Syncon Universal Influenza Vaccine 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
INO-3112 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
INO-3401 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
INO-3510 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
INO-3605 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
INO-3609 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
INO-8000 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
PENNVAX-B 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Pennvax-G 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
VGX-1027 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
VGX-3400X 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
VRC-01 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
DNA Vaccine for Chikungunya 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
DNA Vaccine for H3N2 Influenza 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
DNA Vaccine for H7N9 Universal Influenza 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
DNA Vaccine for MERS Coronavirus Infection 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
DNA Vaccine For Smallpox 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
DNA-based IL-33 + HPV-16 DNA Vaccine 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
INO-1400 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
INO-7103 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
INO-7105 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
MAV-12 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Pennvax-GP 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Inovio Pharmaceuticals, Inc. - Pipeline Analysis 56
Inovio Pharmaceuticals, Inc. - Pipeline Products by Target 56
Inovio Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 58
Inovio Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 59
Inovio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 60
Inovio Pharmaceuticals, Inc. - Recent Pipeline Updates 61
Inovio Pharmaceuticals, Inc. - Dormant Projects 68
Inovio Pharmaceuticals, Inc. - Discontinued Pipeline Products 69
Discontinued Pipeline Product Profiles 69
mifepristone 69
VGX-410C 69
Inovio Pharmaceuticals, Inc. - Company Statement 70
Inovio Pharmaceuticals, Inc. - Locations And Subsidiaries 72
Head Office 72
Other Locations and Subsidiaries 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 74
Disclaimer 74

List of Tables

Inovio Pharmaceuticals, Inc., Key Information 7
Inovio Pharmaceuticals, Inc., Key Facts 7
Inovio Pharmaceuticals, Inc. - Pipeline by Indication, 2014 9
Inovio Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 11
Inovio Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 12
Inovio Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2014 13
Inovio Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 14
Inovio Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 15
Inovio Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 16
Inovio Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 17
Inovio Pharmaceuticals, Inc. - Phase II, 2014 18
Inovio Pharmaceuticals, Inc. - Phase I, 2014 19
Inovio Pharmaceuticals, Inc. - Preclinical, 2014 21
Inovio Pharmaceuticals, Inc. - Pipeline by Target, 2014 57
Inovio Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 58
Inovio Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 59
Inovio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 60
Inovio Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 61
Inovio Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 68
Inovio Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 69
Inovio Pharmaceuticals, Inc., Subsidiaries 72

List of Figures

Inovio Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2014 9
Inovio Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 11
Inovio Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 12
Inovio Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 14
Inovio Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2014 56
Inovio Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2014 58
Inovio Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2014 59
Inovio Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 60

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Biopharmaceutical Industry: AlphaVax, Inc. – Product Pipeline Review – Q2 2011

Biopharmaceutical Industry: AlphaVax, Inc. – Product Pipeline Review – Q2 2011

  • $ 1 500
  • Company report
  • September 2014
  • by Global Markets Direct

- Product Pipeline Review - Q2 2011” provides a detailed overview on the AlphaVax, Inc.’s research and development focus. The report includes data on current developmental pipeline, complete with latest ...

Biopharmaceutical in Japan: Sinovac Biotech Ltd. – Product Pipeline Review – H2 2011

Biopharmaceutical in Japan: Sinovac Biotech Ltd. – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • July 2014
  • by Global Markets Direct

s research and development focus. The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using ...

Pathology in Japan: Eisai Co., Ltd. – Product Pipeline Review – H2 2011

Pathology in Japan: Eisai Co., Ltd. – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • September 2014
  • by Global Markets Direct

Ltd. - Product Pipeline Review - H2 2011” provides a detailed overview on the Eisai Co., Ltd.’s research and development focus. The report includes data on current developmental pipeline, complete ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.